Abstract 68P
Background
ESR1 gene mutation is an important prognostic and predictive biomarker in endocrine resistant metastatic breast cancers. There is limited knowledge on the incidence and types of ESR1 mutations in Indian breast cancer patients.
Methods
The research was conducted in ambispective manner, on HR-positive and HER2-negative MBCs. Next generation sequencing was done on formalin-fixed paraffin embedded (FFPE) tissues. DNA was extracted by enzymatic method, and library preparation was performed using QIAseq Target DNA Panel kit, for ESR1 and PIK3CA genes. Sequencing was done on Illumina HiSeq X series. The NGS output data was analyzed using in-house developed bioinformatics pipeline.
Results
Approximately 80 cases were subjected for NGS after successful DNA extraction and library preparation. Approximately 18 different ESR1 gene mutations were detected in 27.5% cases. Majority (n = 14) were clustered in ligand binding domain. Maximum mutations occurred at codon L536 (n = 8), L536P being the most common. Pathogenic variants D538Q and S463P were also detected. Patients with mutations were frequently above 50 years, post-menopausal, with IDC-NST morphology, grade 2 tumours, with strong ER, moderate PR and Ki67 >14%. The mutations were significantly associated visceral metastasis (p=0.02). The frequency of ESR1 mutations in metastatic samples was 24%, with higher frequency in bones than viscera. The mutations were detected in ovaries, distant lymph nodes, liver, brain and pleura. About 29.4% of treatment naïve MBCs harbored ESR1 mutation. We also detected mutation in a treatment naïve primary breast tumor, in post-aromatase inhibitors (30%) and post-tamoxifen (27.3%) treated samples. About 50% (11/22 patients) of ESR1 mutated patients also had PIK3CA mutations.
Conclusions
The overall frequency of ESR1 mutation in our study was in concordance with earlier studies. Unlike most of the earlier digital PCR-based studies, NGS helped us to detect new variants, whose pathogenic significance has not still been established. We were also able to detect mutations in rare instances, such as treatment-naïve and tamoxifen-treated cases, which warrant further exploration and validation.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Kidwai Memorial Institute of Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
95P - Implementation of TDM and PGx in mRCC patients treated with sunitinib to personalize drug dosing
Presenter: Giorgia Bortolus
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Physician perceptions and the evolving landscape of next generation sequencing (NGS) use across EU4+UK
Presenter: Keerun Khela
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Population-based assessment of outcomes in pancreatic ductal adenocarcinoma (PDAC) patients (pts) with pathogenic germline variants (PGVs)
Presenter: Phoebe Cheng
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Clinical implementation of NGS and ESCAT for optimized cancer therapy
Presenter: AI. Martin-Quesada
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Prevalence of homologous recombination repair deficiency-associated variants in non-selected Portuguese patients with metastatic prostate cancer
Presenter: Tiago Barroso
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Real-world insights in precision oncology: First data of the comprehensive clinico-genomics database network AIO-BNHO-CONNECT (AIO-TF-0122) in Germany
Presenter: Maike Collienne
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Molecular tumor board for advanced cancer patients offers new therapeutic opportunities beyond level 1 ESCAT scale
Presenter: Victor Segui-Manzaneque
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - NICE recommendations and ESMO-MCBS/ESCAT scores for solid tumour drugs
Presenter: Eunice Xing
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Comprehensive analysis of clinical characteristics and germline status among colorectal cancer patients in a tertiary care center in Thailand
Presenter: NUTDANAI ROILA
Session: Cocktail & Poster Display session
Resources:
Abstract